Shanghai Fosun Pharmaceutical's (02196) holding subsidiary has obtained approval from the National Medical Products Administration for the registration application of Levofloxacin Injection.

Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary Chongqing Yaoyou Pharmaceutical Co., Ltd. has obtained approval from the National Medical Products Administration for the registration application of Levofloxacin Injection. The approved indications for this drug include mild, moderate, and severe infections caused by sensitive bacteria: (1) hospital-acquired pneumonia; (2) community-acquired pneumonia; (3) acute bacterial sinusitis; (4) acute bacterial exacerbations of chronic bronchitis; (5) complicated skin and skin structure infections; (6) uncomplicated skin and soft tissue infections; (7) chronic bacterial prostatitis; (8) complicated urinary tract infections; (9) acute pyelonephritis; (10) uncomplicated urinary tract infections; (11) inhalational anthrax (post-exposure). This drug is a chemically developed drug independently researched by the Fosun Pharmaceutical Group (including the company and its holding subsidiaries/units). As of April 2026, the total research and development investment for this drug by the group is approximately RMB 1.94 million (unaudited). According to the latest data from IQVIA CHPA, in 2025, the sales of Levofloxacin Injection in China (excluding the Hong Kong, Macao, and Taiwan regions) were approximately RMB 1.057 billion. The approval of this drug for market will further enrich the product portfolio of the Fosun Pharmaceutical Group.